First AD

Second AD

Optimizing Molecular Profiling for B-ALL Treatment

Video content above is prompted by the following:

In the course of patient assessment, when do you obtain a molecular profile for genetic variants and T-cell biomarkers?

Which team member obtains or orders the test?

Does Moffitt Cancer Center use a preferred assay for its adult patients with relapsed or refractory B-ALL?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

A Multidisciplinary Approach to CAR T-cell Therapy for Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia 

OncLive Insights

Experts discuss the timing and process of obtaining molecular profiles for genetic variants and T-cell biomarkers during patient assessment, including the team member responsible for ordering the test and whether Moffitt Cancer Center uses a preferred assay for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).